Evidence map›Paper›PMID 25653440›Full record

ArticleJournal of virology2015

Role of type I interferon signaling in human metapneumovirus pathogenesis and control of viral replication.

Andrew K Hastings, John J Erickson, Jennifer E Schuster, Kelli L Boyd, Sharon J Tollefson, Monika Johnson, Pavlo Gilchuk, Sebastian Joyce, John V Williams

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Andrew K HastingsDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
John J EricksonDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Jennifer E SchusterDepartment of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri, USA.
Kelli L BoydDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Sharon J TollefsonDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Monika JohnsonDepartment of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Pavlo GilchukDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Sebastian JoyceDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
John V WilliamsDepartments of Pathology, Microbiology & Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA john.williams@vanderbilt.edu.ORCID http://orcid.org/0000-0001-8377-5175
Vanderbilt University · USChildren's Mercy Hospital · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Host Determinants of Human Metapneumovirus Immunity and PathogenesisR01AI085062 · NIAID · VANDERBILT UNIVERSITY · PI John V. Williams · 2010 to 2026
$5.6M
MOLECULAR IMMUNOLOGY OF MINOR HISTOCOMPATIBILITY ANTIGENR01HL054977 · NHLBI · VANDERBILT UNIVERSITY · PI JOYCE, SEBASTIAN · 1995 to 2009
$2.6M
Processing and Presentation of Minor Histocompatibility Antigens that Cause GvHDR01HL121139 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOYCE, SEBASTIAN · 2014 to 2017
$1.6M
Vaccinating at Mucosal Surfaces with Nanoparticle Conjugated Antigen and AdjuvantI01BX001444 · VA · VETERANS HEALTH ADMINISTRATION · PI JOYCE, SEBASTIAN · 2014 to 2022
–
BLRD VA I01 BX001444NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA68485NHLBI NIH HHS HL054977NHLBI NIH HHS R01 HL054977NHLBI NIH HHS R01 HL121139NIAID NIH HHS AI042286NIAID NIH HHS AI085062NIAID NIH HHS N01 AI040079NIAID NIH HHS R01 AI085062NIDDK NIH HHS DK058404NIDDK NIH HHS P30 DK058404NIGMS NIH HHS GM007347NIGMS NIH HHS T32 GM007347
6 · The paper itself

Abstract

unlabelledType I IFN signaling, which is initiated through activation of the alpha interferon receptor (IFNAR), regulates the expression of proteins that are crucial contributors to immune responses. Paramyxoviruses, including human metapneumovirus (HMPV), have evolved mechanisms to inhibit IFNAR signaling, but the specific contribution of IFNAR signaling to the control of HMPV replication, pathogenesis, and adaptive immunity is unknown. We used IFNAR-deficient (IFNAR(-/-)) mice to assess the effect of IFNAR signaling on HMPV replication and the CD8(+) T cell response. HMPV-infected IFNAR(-/-) mice had a higher peak of early viral replication but cleared the virus with kinetics similar to those of wild-type (WT) mice. However, IFNAR(-/-) mice infected with HMPV displayed less airway dysfunction and lung inflammation. CD8(+) T cells of IFNAR(-/-) mice after HMPV infection expressed levels of the inhibitory receptor programmed death 1 (PD-1) similar to those of WT mice. However, despite lower expression of inhibitory programmed death ligand 1 (PD-L1), HMPV-specific CD8(+) T cells of IFNAR(-/-) mice were more functionally impaired than those of WT mice and upregulated the inhibitory receptor Tim-3. Analysis of the antigen-presenting cell subsets in the lungs revealed that the expansion of PD-L1(low) dendritic cells (DCs), but not PD-L1(high) alveolar macrophages, was dependent on IFNAR signaling. Collectively, our results indicate a role for IFNAR signaling in the early control of HMPV replication, disease progression, and the development of an optimal adaptive immune response. Moreover, our findings suggest an IFNAR-independent mechanism of lung CD8(+) T cell impairment. IMPORTANCE: Human metapneumovirus (HMPV) is a leading cause of acute respiratory illness. CD8(+) T cells are critical for clearing viral infection, yet recent evidence shows that HMPV and other respiratory viruses induce CD8(+) T cell impairment via PD-1-PD-L1 signaling. We sought to understand the role of type I interferon (IFN) in the innate and adaptive immune responses to HMPV by using a mouse model lacking IFN signaling. Although HMPV titers were higher in the absence of type I IFN, virus was nonetheless cleared and mice were less ill, indicating that type I IFN is not required to resolve HMPV infection but contributes to pathogenesis. Further, despite lower levels of the inhibitory ligand PD-L1 in mice lacking type I IFN, CD8(+) T cells were more impaired in these mice than in WT mice. Our data suggest that specific antigen-presenting cell subsets and the inhibitory receptor Tim-3 may contribute to CD8(+) T cell impairment.

Indexed as

Analysis of VarianceAnimalsAntigen-Presenting CellsCD8-Positive T-LymphocytesFlow CytometryGene Expression RegulationHepatitis A Virus Cellular Receptor 2HumansInterferon Type IMetapneumovirusMiceMice, Inbred C57BLMice, KnockoutOximetryParamyxoviridae InfectionsReal-Time Polymerase Chain ReactionHavcr2 protein, mouseHepatitis A Virus Cellular Receptor 2Interferon Type IReceptors, Virus

Identifiers

PMID25653440
PMCPMC4442394
OpenAlexW2126740323

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.